Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-03-01
|
Series: | Journal of Community Hospital Internal Medicine Perspectives |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/20009666.2018.1454787 |
id |
doaj-1a3b2049ee3a4befb2f496b945886daf |
---|---|
record_format |
Article |
spelling |
doaj-1a3b2049ee3a4befb2f496b945886daf2020-11-25T00:43:17ZengTaylor & Francis GroupJournal of Community Hospital Internal Medicine Perspectives2000-96662018-03-0182879110.1080/20009666.2018.14547871454787Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicityAdnan Asif Parvez Ghias0Shahzeem Bhayani1David J. Gemmel2Sudershan K. Garg3St. Elizabeth Health CenterSt. Elizabeth Health CenterSt. Elizabeth Health CenterHematology and Oncology, Mercy HealthGastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case discusses rapidly progressive dyspnea and heart failure in an elderly male with metastatic GIST who was started on imatinib. Although reported as a rare and sporadic side effect of imatinib, the current case illustrates rapidity and the clinical significance of cardiotoxicity, with onset at 2 weeks. Cases of imatinib-induced cardiotoxicity can range from being mild ventricular dysfunction to overt heart failure. Prior to starting imatinib, our patient had a history of hypertension. He subsequently ended up developing heart failure as acknowledged by the echocardiogram (ECHO). In general, elderly with preexisting cardiovascular comorbidity are at greater risk. The goal in such situations is immediate discontinuation or reduction of the imatinib dosage. The case prompts for awareness of imatinib cardiotoxicity. Moreover, a pretreatment cardiac assessment along with monitoring throughout therapy is therefore advisable. Also, imatinib-induced cardiotoxicity should be differentiated from imatinib-associated fluid retention, in which ECHO findings can be normal. This case report raises the concern for accelerated cardiotoxicity profile of imatinib. Further prospective studies with multidisciplinary input are needed to establish this association further.http://dx.doi.org/10.1080/20009666.2018.1454787Gastrointestinal stromal tumorsGISTsimatinibcardiac toxicityheart failurefluid retentionimatinib toxicityrareLV dysfunction |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Adnan Asif Parvez Ghias Shahzeem Bhayani David J. Gemmel Sudershan K. Garg |
spellingShingle |
Adnan Asif Parvez Ghias Shahzeem Bhayani David J. Gemmel Sudershan K. Garg Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity Journal of Community Hospital Internal Medicine Perspectives Gastrointestinal stromal tumors GISTs imatinib cardiac toxicity heart failure fluid retention imatinib toxicity rare LV dysfunction |
author_facet |
Adnan Asif Parvez Ghias Shahzeem Bhayani David J. Gemmel Sudershan K. Garg |
author_sort |
Adnan Asif Parvez Ghias |
title |
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity |
title_short |
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity |
title_full |
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity |
title_fullStr |
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity |
title_full_unstemmed |
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity |
title_sort |
rapidly progressive dyspnea in gastrointestinal stromal tumor (gist) with imatinib cardiac toxicity |
publisher |
Taylor & Francis Group |
series |
Journal of Community Hospital Internal Medicine Perspectives |
issn |
2000-9666 |
publishDate |
2018-03-01 |
description |
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case discusses rapidly progressive dyspnea and heart failure in an elderly male with metastatic GIST who was started on imatinib. Although reported as a rare and sporadic side effect of imatinib, the current case illustrates rapidity and the clinical significance of cardiotoxicity, with onset at 2 weeks. Cases of imatinib-induced cardiotoxicity can range from being mild ventricular dysfunction to overt heart failure. Prior to starting imatinib, our patient had a history of hypertension. He subsequently ended up developing heart failure as acknowledged by the echocardiogram (ECHO). In general, elderly with preexisting cardiovascular comorbidity are at greater risk. The goal in such situations is immediate discontinuation or reduction of the imatinib dosage. The case prompts for awareness of imatinib cardiotoxicity. Moreover, a pretreatment cardiac assessment along with monitoring throughout therapy is therefore advisable. Also, imatinib-induced cardiotoxicity should be differentiated from imatinib-associated fluid retention, in which ECHO findings can be normal. This case report raises the concern for accelerated cardiotoxicity profile of imatinib. Further prospective studies with multidisciplinary input are needed to establish this association further. |
topic |
Gastrointestinal stromal tumors GISTs imatinib cardiac toxicity heart failure fluid retention imatinib toxicity rare LV dysfunction |
url |
http://dx.doi.org/10.1080/20009666.2018.1454787 |
work_keys_str_mv |
AT adnanasifparvezghias rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity AT shahzeembhayani rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity AT davidjgemmel rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity AT sudershankgarg rapidlyprogressivedyspneaingastrointestinalstromaltumorgistwithimatinibcardiactoxicity |
_version_ |
1725279366534922240 |